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Abstract 
 
Background: Data on the prevalence of CYP2C9 and VKORC1 genes and their influence on 
anticoagulant effect and warfarin dose in stroke patients are scarce. The aim of this study was 
to determine the occurrence and significance of these gene polymorphisms and to establish 
pharmacogenetic algorithm to estimate the dose of introduction. Also, the goal was to 
determine tailored safety and intensity of anticoagulation response depending on the allelic 
variants and their impact on the clinical outcome in acute stroke patients in Croatia.  
Methods: A total of 106 consented acute stroke patients were tested for CYP2C9*2,*3 and 
VKORC1 1173C>T gene polymorphisms. We estimated the dose of introduction and 
monitored anticoagulant effect obtained by INR values, time to reach stable dose, stable 
maintenance dose, time spent within the therapeutic/supratherapeutic INR range, occurrence 
of dosage side effects and clinical outcome depending on genotypes. 
Results: We found that 83% of stroke patients in our study were carriers of multiple allelic 
variants. The predicted initial dose correlated with the stable warfarin maintenance dose 
(p=0.0311) and we correctly estimated the dose for 81.5% of 61.3% of study patients who 
required higher/lower doses than average. Warfarin dosage complications were slightly more 
frequent among the carriers of CYP2C9*2,*3 compared to the carriers of VKORC1 1173 T 
alleles (68. 9% versus 62.5%), but their occurrence did not affect the final clinical outcome. 
Conclusion: Our data indicated rapid and safe anticoagulation achieved by using 
pharmacogenetically-predicted warfarin dose in high-risk acute stroke patients without 
increasing the risk of warfarin dosage complications in elderly population. 
 
Key words: stroke, warfarin, genetic polymorphism, CYP2C9, VKORC1 
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Introduction 
Warfarin is the most widely prescribed anticoagulant owing to its effectiveness in primary and 
secondary prevention and treatment of thromboembolic events coupled with its low cost, in 
spite of the emergence of newer anticoagulants like dabigatran, rivaroxaban, apixaban (1,2). 
However, its use is associated with significant morbidity and mortality and makes it the 
second leading drug-related cause for emergency hospitalization. Most drug-related adverse 
events emerge during the early initiation of therapy which is a challenging and demanding 
process. Risks for hemorrhage or thromboembolism as the consequences of under or over-
anticoagulation range from 16% to 25% and these events are more frequent during the 
initiation period than later (3,4,5). These early problems depend on multiple environmental 
and genetic factors and are related to warfarin  narrow therapeutic INR (International 
Normalized Ratio) range and at least 20-fold interindividual variability in warfarin sensitivity 
(6). 
Common polymorphisms of CYP2C9 and VKORC1 genes have a strong influence on 
interindividual warfarin sensitivity, variability of anticoagulant effect and dose requirement, 
therefore accounting for more than one-third of variances associated with a stable therapeutic 
dose (7,8). An association between the CYP2C9 gene polymorphisms, time to reach first 
therapeutic and supratherapeutic INR values and increased risk of bleeding during the 
initiation phase of anticoagulant therapy has been well documented. Two alleles, CYP2C9 
*2(Arg144Cys) and CYP2C9*3 (Ile359Leu) out of > 30 CYP2C9 discovered alleles are 
considered strong risk factors for over-anticoagulation (9). Studies of single nucleotide 
polymorphisms (SNPs) of VKORC1 -1636G>A and 1173C>T have confirmed the significant 
influence of VKORC1 gene polymorphisms on warfarin sensitivity and dosing (10-12). 
CYP2C9 and VKORC1 polymorphisms may explain up to 54 % of warfarin dose variabilities 
(13-15). Previous studies have been mainly focused on establishing genetic-based warfarin-
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dosing algorithms, while only a few studies have investigated the effectiveness of their 
clinical application (16-18). 
Patients with cardioembolic stroke and the stroke consequent to the dissection of extracranial 
or intracranial arteries or cerebral sinus thrombosis require urgent anticoagulant therapy 
initiation for secondary stroke prevention. These patients are at a 5-7% risk of embolic stroke 
recurrence within the first week. At the same time they have an increased risk of bleeding into 
the infarct zone due to the nature of the ischemic brain damage or to thrombolytic therapy 
side effects, with subsequent deterioration of neurological deficits (19-23). Therefore, those 
patients are also at increased risk of warfarin dosage side effects, notably of warfarin-induced 
brain hemorrhage and it is essential for them to have their initial doses selected on the basis of 
individual genotype to prevent the additional risk of dosage related complications. 
The goals of the current study were to determine the frequencies of SNPs in the CYP2C9 and 
VKORC1 genes in our group of acute stroke patients, to individualize therapy by using 
pharmacogenetic-based warfarin-dosing algorithm and to determine tailored security and 
intensity of anticoagulation response depending on the CYP2C9 and VKORC1 genotypes. 
We also gauged the impact of these polymorphisms on clinical outcome in studied patients.  
 
Patients and methods 
 
Patients   
In the time period between October 2010 till April 2011, 307 patients were hospitalized with 
acute ischemic stroke in the Stroke Unit, Department of Neurology, UHC Zagreb. After 
obtaining ethical permission, the study was conducted in 106 consented patients with acute 
stroke who had an indication for urgent anticoagulation. Among them, 36 patients were 
previously anticoagulated with warfarin. Inclusion and exclusion criteria are listed in Table 1.  
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Materials and methods  
Upon admission, blood samples (10 ml) were taken for INR measurement and genotyping. 
Low molecular weight heparin (LMH) had been administered during first five to seven days 
since admission, before the initial dose of warfarin was introduced. The initial dose of 
warfarin was calculated by using non-profit website published algorithm 
http://www.WarfarinDosing.org., which included some demographic data, indications for 
warfarin therapy, concomitant medications (amiodarone, carmabazepine and phenytoin were 
included) and CYP2C9 *2*3 and VKORC1 1173C>T genotypes (16,23). During 
hospitalization, the following data were recorded for each patient: gender, age, weight, height, 
indications for warfarin therapy, several INR values depending on the day of therapy 
introduction, predicted dose, dose of introduction, stable maintenance dose, dosage- 
dependent side effects (minor or major bleeding) and clinical outcome at the end of the study 
reported as mRS (modified Rankin Scale) (23, 24). 
After the initial pharmacogenetically predicted warfarin dose had been assessed, we 
introduced the calculated “mini loading dose”(dose of introduction) of warfarin for first two 
days (Table 2) (25). Doses were subsequently adjusted depending on the measured INR 
values. The values of INR were recorded at admission, on the first day of warfarin therapy 
introduction, after 48 hours, 72 hours, on days 5, 7, 14 and on day 21 of warfarin therapy 
introduction when the study was terminated. Target INR value was >2, therapeutic range was 
2-3 and supratherapeutic values were determined as INR >3.1. Stable maintenance dose was 
defined as the warfarin dose at which a patient was maintained within the therapeutic INR 
range and which did not change during three consecutive INR measurements for at least five 
days.  
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Side effects   
Warfarin dosage side effects were defined as minor or major bleeding. Minor bleeding was 
defined as small subcutaneous hemorrhage, microhematuria or slight gingival or vaginal 
bleeding. Major hemorrhage was classified into two subgroups: a) bleedings that did not 
require interruption of therapy, such as mild hemorrhage into the infarct zone without 
worsening of neurological deficit, b) bleedings that required interruption of warfarin therapy, 
such as large intracerebral hematoma with deterioration of neurological deficit, extensive 
gastrointestinal or urogenital bleeding.         
 
Endpoints                                                                                                                                            
The primary endpoints to determine were the following:                                                               
- frequencies of CYP2C9 *2,*3 and VKORC1 C1173T alleles in acute stroke patients                 
- time to reach the first therapeutic INR                                                                      
- time to reach stable maintenance dose, and stable maintenance dose according to genotype 
The secondary endpoints to determine were as follows: 
- time and the percentage of time spent in therapeutic and supratherapeutic INR range                                       
- incidence of warfarin dosage side effects according to genotype 
- association of the severity of neurological deficit at discharge reported as mRS with age 
- association of final clinical outcome with the occurrence of warfarin dosage complications. 
 
Genotyping procedures   
 
DNA was isolated from whole blood by salting out method. In this study, three SNPs were 
genotyped by TaqMan® Drug Metabolism Genotyping Assays: CYP2C9*2 (rs1799853) with 
assay ID C_25625805_10, CYP2C9*3 (rs1057910) with assay ID C_27104892_10 and 
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VKORC1 1173C>T (rs 9934438) with assay ID C_30204875_10. The genotyping was 
performed by the Applied Biosystems 7500 Real Time PCR System according to the 
manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). All assays were run 
in 96 well plates under the same instrument conditions: 2 min at 50°C, 10 min at 95°C, 
following 50 cycles of 15 sec at 92°C with 90 sec at 60°C extension time. For each SNP, the 
25 µl PCR reaction mixture per well consisted of 1.25 µl TaqMan® Drug Metabolism 
Genotyping Assay Mix (specific for each polymorphism), 12.5 µl TaqMan® Universal PCR 
Master Mix and 5 -20 ng of genomic DNA diluted in 11.25 µl dH20 (26). 
 
Statistical Analysis 
Quantitative variables are presented as an arithmetic mean (AM) and standard deviation (SD) 
when distribution was normal, otherwise as confidence interval (95%CI), median or 
Interquartile range (IQR). 
Qualitative variables are presented as frequency and proportion (such as frequency of alleles 
or group of alleles, time and percentage of time spent in therapeutic INR values).  
Student's t-test or Mann-Whitney U-test were used for comparison among the groups for 
quantitative variables (time required to achieve the target INR, time to achieve stable 
maintenance dose). χ2-test was used for comparison among the groups for qualitative 
variables. Analysis of variance (ANOVA) or Kruskal-Wallis test, depending on distribution, 
were used for comparing the groups for quantitative variables. The Spearman rank correlation 
was used to characterize associations among quantitative variables. Results were deemed 
statistically significant at the 5% level (p<0.05).                                                        
The analysis was carried out by using statistical software package STATISTICA ver. 6.0 
(StatSoft Inc., Tulsa, OK, USA ). 
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Results   
 
Demographic data and the prevalence of CYP2C9 and VKORC1 gene polymorphisms in 
stroke patients 
The study included 106 Caucasian patients from Croatia, CEU (56.6% female and 43.4% 
male), with the mean age of 67.6 years (65.83-70.27, 95%CI). Out of them, 14.15% were 
younger than 49 years, while 54.76% were older than 71 years. 
The most common genotypes were VKORC1 1173CC (49.5%) and CYP2C9 wt/wt 
(41.5%).Genotypes with reduced enzyme activity, VKORC1 1173TT and CYP2C9 *2,*3 were 
present in 11.3% and 17.92% of patients respectively, as shown in Table 3.                                 
 
Time to reach the first target INR value, proportion of time within the therapeutic INR range 
and the time spent within supratherapeutic INR values depending on genotype 
Target INR value was ≥ 2, therapeutic INR range was 2-3 and supratherapeutic INR> 3.1. 
Patients achieved the first target INR ≥ 2 for an average of 4.16 days (4.12-4.66, 95%CI). 
Significant difference was observed by applying the method of linear interpolation between 
genotypes in the time needed to achieve the target INR (p = 0.0257), assuming that the wild 
type was the reference group (Table 3). Patients spent 16.09 days (15.69-16.48, 95% CI) 
within the therapeutic INR range or an average of 79.54% (74.75-78.51, 95%CI) of the time. 
The carriers of  VKORC1 1173TT and at least one variant of CYP2C9 allele 
(wt/*2,wt/*3,*2/*2,*2/*3,*3/*3) spent the longest proportion of time within the therapeutic 
INR range (84.19%). "Wild" homozygotes for both genes spent the shortest proportion of 
time (74.32%) within therapeutic INR range, but without statistically significant difference 
among genotype groups (p = 0.370). The carriers of CYP2C9 (wt/*2, wt /*3,*2/*2) genotypes 
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spent the longest time with supratherapeutic INR values (> 3.1), i. e. a period of 7.68 days and 
they mostly achieved supratherapeutic INR values.  
 
The average estimated dose, dose of introduction, stable maintenance dose and average time 
of achieving the stable maintenance dose depending on genotype 
 Average estimated dose (De) for all patients was 3.82 mg (3.63- 4.20, 95% CI) and the De 
differs significantly between genotypes (p=0.000). The calculated “mini loading dose” (dose 
of introduction, Di) of warfarin for each patient was introduced. The carriers of “wild” 
CYP2C9 /VKORC1 genotypes required the highest Di of 9 mg (8.38-9.62, 95% CI), while the 
carriers of VKORC1 1173 TT and CYP2C9 (wt/*2,wt/*3,*2/*2,*2/*3,*3/*3) defective alleles 
required only 4.26 mg (2.70-5.82, 95%CI). The average stable daily maintenance dose (Dm) 
was up to 3.51 mg (3.44- 4.08, 95% CI) and significantly correlated with the combination of 
CYP2C9 and VKORC1 genotypes (p=0.000), as shown in Table 3. The predicted initial dose 
correlated with the stable warfarin maintenance dose (Dm) (p=0.0311). 
The average time of achieving the Dm amounted to 10.00 (9.96-10.69, 95% CI) days and the 
stable Dm was most rapidly achieved (in 7 days) by the carriers of homozygous defective 
alleles for both genes (CYP2C9 *2*2 or *2*3/ VKORC1 1173TT). Since 61.3% (N=65) of 
106 study patients required higher (N=15) or lower (N=50) doses of warfarin than usual 
(<3mg or >6 mg), we correctly estimated the dose for 81.5% of those 65 patients. 
 
Warfarin dosage side effects and final neurological deficit (mRS) at the discharge depending 
on genotype 
Warfarin dosage complications were slightly more frequent among the carriers of CYP2C9 
*2*3 alleles (68.9%) when compared to the carriers of VKORC1 1173C>T alleles (62.5%). 
Severe dose dependent side effects were more common in the carriers of VKORC1 1173TT 
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genotype (62.5 %) and the carriers of two defective CYP2C9 *2 or *3 alleles (37.5%), but 
without significant difference between genotypes (p=0.0698). Our data indicate no significant 
correlation between the occurrence of warfarin dosage side effects and the proportion of time 
spent within the therapeutic INR range (p = 0.5652), although the occurrence of major 
bleeding was higher in patients (9.59%) who spent more time outside the therapeutic INR 
range. The age of the patients did not affect the final neurological outcome expressed by mRS 
(p =0.1562), although all fatal outcomes were observed in patients older than 71 years (42%).                          
The occurrence of side effects dependent on warfarin dosage did not have an impact on final 
clinical outcome (p=0.1198), as shown in Table 4. We also did not find association of final 
neurological outcome with the percentage of the time spent within the therapeutic INR range 
(p=0.5652) or with the time required to achieve a stable therapeutic dose.  
 
Discussion 
The introduction of warfarin into therapy is a challenging and tedious process that can lead to 
serious side effects like bleeding, especially among highly vulnerable patients, such as 
patients with acute ischemic stroke. In this study we analyzed the influence of CYP2C9 and 
VKORC1 1173 C>T gene polymorphisms on the prediction of the initial dose of warfarin in 
Caucasian Croatian patients with acute stroke and their impact on the achievement of a fast 
and stable anticoagulant effect expressed by therapeutic INR range (2-3) and a stable 
therapeutic dose. Target INR values (≥ 2) were achieved at an average time of 4.16 days. 
Allelic variants that have contributed to the earlier achievement of target INR values were 
homozygous "defective" variants of VKORC1 and CYP2C9 genes; patients with these variants 
have attained the target INR already at 1.35 days. The longest time for the anticoagulant effect 
and achievement of the target INR values was needed by the carriers of “wild” VKORCl and 
CYP2C9 homozygous alleles (5.05 days).  
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The shortest proportion of time spent within the therapeutic INR range with slower 
achievement of target INR was observed in the group of carriers of homozygous "wild” type 
alleles.  
Explanation for this could be the observation that “wild” type VKORC1 allele carriers are 
often also carriers of rare mutations and require significantly higher doses or can even 
develop resistance to warfarin (11). However, these mutations are not analyzed in routine 
clinical practice and we do not have these data. The longest proportion of time spent within 
the therapeutic INR range was observed for the group of patients carriers of defective alleles. 
Such patients require lower doses of warfarin and they are less likely carriers of VKORC1 rare 
mutations,  all of which could contribute to more accurate dosing (27,28). 
Our data suggest the dominant effect of CYP2C9 gene polymorphisms on early achievement 
of target INR and supratherapeutic INR> 3.1 values, which is consistent with some published 
data (12-15,29,30). However, opposite data were also obtained, pointing to the greater role of 
VKORC 11173TT in achieving the target INR, although CYP2C9 *2 and *3 allele variants 
were responsible for the earlier achievement of supratherapeutic INR values (31,32). 
Estimated initial doses and stable maintenance doses did not differ among the group of 
genotypes, indicating that our pharmacogenetically based warfarin-dosing algorithm could 
effectively predict the actual warfarin maintenance dose, providing clinicians with a reliable 
tool for managing successful anticoagulation (33-35). Homozygous carriers of 
VKORC1/CYP2C9 defective alleles required the lowest daily maintenance dose of 1 mg, 
while the highest dose of 6 mg per day was needed by homozygous "wild" type carriers. 
Relatively high proportion (61.3%) of our patients required doses that are higher or lower than 
the average, which is a significantly higher proportion compared to data from Anderson's 
study where 46% of patients required lower or higher doses than average (14). This difference 
could be explained by possible different frequencies of tested polymorphisms in general 
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population. Patients with embolic stroke, particularly cardioembolic stroke caused by atrial 
fibrillation as was the case in 77% of our respondents, have a 5-7% risk for embolic stroke 
recurrences within 7-12 days after the initial stroke, with immediate risk for intracerebral 
hemorrhage as the result of damage related to the nature of the disease (20,21). For this 
vulnerable group of patients (who are under- or over anticoagulated), it is crucial to achieve 
anticoagulant effect and stable therapeutic dose as soon as possible, while pharmacogenetic 
testing seems valuable and promising. 
In this study, the average time of achieving stable maintenance dose was up to 10 days. An 
interesting finding is in one of our patients, the carrier of VKORC1CT/ CYP2C9 wt/wt 
genotype, whose estimated initial dose was 4.5 mg according to pharmacogenetically based 
algorithm. He reached the target INR very slowly and only after 19 days achieved the stable 
therapeutic dose of 12 mg per day, which was more than twice the estimated value, although 
he did not receive any concomitant therapy. This might be explained in several ways: he is a 
very fast metabolizer for CYP2C9 due to possibly different transcriptional regulation of 
CYP2C9 (34); he is the carrier of rare VKORC1 mutations predisposing resistance or has a 
molecular mechanism for warfarin resistance independent of the regulation of the CYP2C9 
and VKORC1 genotypes (36,37).                                       
We confirmed the relatively high prevalence of 83% of VKORC1 and CYP2C9 multiple allele 
carriers among our stroke patients with one (27.3%), two (46.2%) or more defective alleles 
that require significantly lower doses compared to the "wild" type carriers. This was also 
demonstrated by the research of Caldwell and Ruan in whose study 73.2 % of patients were 
carriers of one or more CYP2C9 or VKORC1 polymorphisms (38,39). Stroke patients who 
stand to benefit most from genotyping are precisely those who have the greatest number of 
deficient polymorphisms.                                                                                                                                   
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The presented data are consistent with previous studies that have pointed to the dominant 
impact of VKORC1 gene polymorphisms on stable maintenance dose.  
Studies of inter-ethnic differences in sensitivity to warfarin confirmed that the 
VKORC1 polymorphism had significantly greater influence on the variability of dose 
in Asians and Caucasians than in Afro-Americans as the result of race-specific 
differences in the frequency of VKORC1 polymorphisms (40-43). A studies conducted  
confirmed that this is due to differences in MAFs (minor allele frequency) across racial 
groups. As the MAF increases, the percentage of variation in dose explained by minor allele 
increases, with the highest variance explained at MAF of 60% to 70%. Minor allele 
frequencies for VKORC1 -1639G>A in Asian, white,  and black population are, 0.91, 0.39, 
and 0.11 respectively.  The frequencies are calculated by using genotype information from 
subjects in International Warfarin Pharmacogenetics Consortium (44). 
Although the variability in dose explained by VKORC1 differed by racial groups at the 
population level, possession of the minor allele (-1639A or 1173T) at an individual level was 
associated with the similar decrease in warfarin dose requirement irrespective of race. 
CYP2C9 allele frequencies also vary considerably among racial groups.  Minor allele 
CYP2C9*2 frequencies in the white, Asian and black population are estimated to be 0.13, 0, 
and 0.03 respectively, and for CYP2C9*3 frequencies they are 0.07, 0.04 and 0.02, 
respectively, according to IWPC (International Warfarin Pharmacogenetics Consortium). 
Thus, aggregate minor allele frequencies for CYP2C9 range from 4% in Asians and 5% in 
blacks to 20% in whites, and these differences may account for some of the population-level 
differences in the use of warfarin-dosing algorithms in racial groups. Smaller range of the 
CYP2C9 allele frequencies across racial groups compared to VKORC1 is the reason why 
relative contribution to racial differences in dosing is larger for VKORC1 than for CYP2C9.                            
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In Croatian population, the prevalence of variant CYP2C9*2 and *3 alleles is estimated to be 
35% (Božina), which is similar to some other data published for Caucasians (41,43). 
Additional CYP2C9 variant alleles with reduced activity (CYP2C9*5,*6,*8, and *11) 
contribute to dose variability among African Americans. Other genes that could predict 
warfarin dose, but with much lower impact, are CYP4F2 (primary liver vitamin K1 oxidase 
that catalyzes the metabolism of vitamin K1) and CALU (coding for Calumenin, Ca2+-
binding protein) in some but not all populations (44,45).                                       
Most of the side effects related to warfarin therapy occur at the very beginning of the drug 
introduction, in our study mostly between 6-12 days. The incidence of warfarin dosage 
complications did not exceed the incidence stated results of published research where it 
ranged from 5-17%, or even up to 25% (46-48). We found no significant association of the 
development of warfarin dosage complications with the proportion of the time spent within 
the target therapeutic INR range, although the incidence of major bleeding occurred in those 
subjects who spent more time outside the therapeutic INR range (9.59% of respondents). We 
found that warfarin dosage complications were slightly more frequent in the carriers of 
defective CYP2C9 alleles compared to the carriers of defective VKORC1 alleles (68.9% 
versus 62.5%). Serious dosage-related complications were more frequent among the carriers 
of both CYP2C9 defective alleles that commonly contribute to over-anticoagulation. Similar 
observations of an increased risk of bleeding among the carriers of CYP2C9 *2 and *3 alleles 
have been reported in some previous studies, with almost 3-fold increase in risk in the carriers 
of *3 alleles (10,49-50). Among patients with major hemorrhage, three had discrete 
hemorrhagic transition into the infarct zone confirmed by brain CT findings without any signs 
of clinical deterioration. We did not interrupt warfarin therapy in these patients, but adjusted 
the dose with careful monitoring of INR, clinical parameters and brain CT. We also continued 
warfarin therapy in four patients with the occurrence of microhematuria and in one with 
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vaginal bleeding, because we estimated that they had higher risk of serious thromboembolic 
events consequential to the interruption of therapy compared to the symptoms caused by the 
warfarin dosage side effects. In four patients, INR values were within therapeutic range, while 
three patients with defective CYP2C9 alleles had INR>3.1. Three days after completing the 
follow-up study, one patient with VKORC1 1173TT and CYP2C9 *2/*3 genotypes developed 
an extensive gastrointestinal bleeding despite the fact that INR values were within the 
therapeutic range. We applied 20 mg vitamin K followed by intravenous infusion of 690 ml of 
fresh frozen plasma without the need for blood transfusion and the patient has good clinical 
recovery. 
Results of large studies confirmed that the incidence and prevalence of atrial fibrillation, 
which is the most common cause of cardioembolic stroke, increase with age (51). In light of 
these findings, clinical significance of our study lies in the fact that we pointed to a safe 
therapeutic intervention using pharmacogenetically-predicted warfarin dose, particularly in 
elderly acute stroke patients (54.76% were older than 71 years). We found no association of 
warfarin dosage complications with age or with the final clinical outcome reported as mRS, 
although all fatal outcomes were observed in patients aged over 71 years. We primarily 
related such outcomes to the severity of the initial brain damage caused by stroke (49,52-53). 
 
Conclusions                                                                                                                                             
Data from our study confirmed the relatively high prevalence of VKORC1 and CYP2C9 
multiple allele carriers among Croatian patients with ischemic stroke (83%), which has a 
significant impact on required therapeutic dose. By using the pharmacogenetically-based 
warfarin-dosing algorithm that includes CYP2C9 and VKORC1 genotypes, we correctly 
estimated the required dose for 81.5% of 61.3 % of patients who needed higher or lower than 
average doses, which is crucial for rapid and safe anticoagulation. Bearing in mind that over 
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33% (in some studies even 42%, in Croatian population about 35%) of patients with acute 
stroke require immediate application of anticoagulant therapy, the clinical value of this study 
lies in the fact that we pointed to the safe therapeutic intervention by using 
pharmacogenetically-predicted warfarin dose in this high-risk group of patients without 
increasing the risk of warfarin dosage complications in elderly population (54,55). 
 
References: 
1. Diener HC1, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, 
Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in 
patients with atrial fibrillation and previous transient ischaemic attack or stroke: a 
subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-63. 
2. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 
third edition – 2005 update. Br J Haematol 2006;132:277–285. 
3. Bejth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking 
coumarins. Curr Hematol Rep 2002;1:41-49. 
4. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE.Death 
and disability from warfarin-associated intracranial hemorrhages. Am J Med 
2007;120:700-705 
5. Penning-van Beest FJA, van Meegen E, Rosendaal FR. Characteristics of 
Anticaogulation Therapy and Comorbidity Related to Overanticoagulation. Thromb 
Haemost 2001;86:569-74 
6. Wittkowsky AK. Factors associated with INR elevation and bleeding complications 
during Warfarin therapy. Arch Intern Med 2005;165:703. 
7. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future 
challenges. Pharmacogenomics J 2007;7:99-11. 
17 
 
8. Ingelman-Sundberg M1, Sim SC, Gomez A, Rodriguez-Antona C. Influence of 
cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, 
pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526. 
9. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse 
drug reactions. Toxicology 2003;192:23-32. 
10. Sanderson S, Emery J, Higgins J. Cyp2C9 gene variants, drug dose, and bleeding risk 
in warfarin-treated patients:A HuGEnet systematic review and meta-analysis. Genet 
Med 2005;7:97-104 
11. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, 
Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. 
Mutations in VKORC1 cause warfarin and multiple coagulation factor deficiency type 
2. Nature 2004;427:537-541 
12. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, 
Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on 
transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93. 
13. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, 
Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic 
polimorphism and patient characteristics upon warfarin dose requirements:proposal 
for  a new dosing regimen. Blood 2005;106:2329-2333. 
14. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, 
May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators. 
Randomized trial of genotype –guided versus standard warfarin dosing in patients 
initiating oral anticoagulation. Circulation 2007;116:2563-2570. 
18 
 
15. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder 
MW. Estimation of warfarin maintance dose based on VKORC1(-1639G>A) and 
CYP2C9 genotypes. Clin Chem 2007;53:1199-1205. 
16. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, 
Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, 
Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic 
and clinical factors to predict the therapeutic dose of warfarin.Clin Pharmacol Ther 
2008;84:326-31. 
17. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin 
dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64. 
18. Kaur A, Khan F, Agrawal SS, Kapoor A, Agarwal SK, Phadke SR. Cytochrome P450 
(CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene 
polymorphisms & their effect on acenocoumarol dose in patients with mechanical 
heart valve replacement. Indian J Med Res 2013;137:203-9. 
19. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic 
stroke in population-based incidence studies. Neurology 2004;62:569-573.  
20. Ay H, Gungor L, Arsava EM, Rosand J, Vangel M, Benner T, Schwamm LH, Furie 
KL, Koroshetz WJ, Sorensen AG. A score to predict early risk of recurrence after 
ischemic stroke. Neurology 2010;74:128–135.  
21. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, 
Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco 
RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart 
Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical 
Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. 
Guidelines for the prevention of stroke in patients with stroke or transient ischemic 
19 
 
attack: a guideline for healthcare professionals from the american heart 
association/american stroke association. Stroke 2011;42:227-76. 
22. Matijević V, Alvir D, Malojčić B, Unušić L, Supe S, Boban M, Bujan-Kovač A, 
Habek M, Poljaković Z. Systemic thrombolysis with recombinant tissue plasminogen 
activator in acute ischemic stroke: first Croatian experiences. Neurol Sci 2010;31:693-
7. 
23. Habek M, Supe S, Poljaković Z, Gelpi E, Alesch F, Ozretić D, Brinar VV. Subacute 
brainstem angioencephalopathy: favorable outcome with anticoagulation therapy. J 
Neurol Sci 2008;275:167-9. 
24. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke 
1988;19:1497-1500. 
25. FDA Approves Updated Warfarin (Coumadin) Prescribing Information: New Genetic 
Information May Help Providers Improve Initial Dosing Estimates of the 
Anticoagulant for Individual Patients, Available at  
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement/2007/ucm108967.ht
m  Accessed: July 14, 2009 
26. National Academy of Clinical Biochemistry (NACB). Draft Guidelines and 
Recommendations for Laboratory Analysis and Application of Pharmacogenetics to 
Clinical Practice. 3rd Draft, Dec 2007 Version. Accessed June 1, 2010. Available at 
URL address: 
http://www.aacc.org/members/nacb/LMPG/OnlineGuide/DraftGuidelines/Pharmacoge
netics 
27. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative 
contribution of CYP2C9 and VKORC1 genotypes and early INR response to the 
20 
 
prediction of warfarin therapy sensitivity during intiation of therapy. Blood 
2009;113:3925-30. 
28. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker 
P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, 
Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9 and 
CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 
2009;5(3):e1000433. 
29. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on 
warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin 
Pharmacol 2009;65:365-75. 
30. Tanaka KD, Kawai YK, Ikenaka Y, Harunari T, Tanikawa T, Fujita S, Ishizuka M. A 
novel mutation in VKORC1 and its effect on enzymatic activity in Japanese warfarin-
resistant rats. J Vet Med Sci 2013:75:135-9. 
31. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, 
Grandone E, Margaglione M. A polymorphism in the VKORC1 Gene associated with 
an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 
2005;105:645-649. 
32. Higashi MK, Veenstra DL, Kondo LM. Association between CYP2C9 genetic variants 
and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-
1698. 
33. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, 
Roden DM, Stein CM. Genetic Determinants of Response to Warfarin during Initial 
Anticoagulation. N Engl J Med 2008;358:999-1008. 
21 
 
34. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing 
enhances the efficacy and safety of anticoagulation: a prospective randomized 
controlled study. Clin Pharmacol Ther 2008:460-70. 
35. Lenzini P, Grice G, Milligan P, Gatchel S, Deych E, Eby C, Burnett R, Clohisy J, 
Barrack R, Gage B. Optimal initial dose adjustment of warfarin in orthopedic patients. 
Ann Pharmacother 2007;41:1798-804. 
36. Mwinyi J, Nekvindová J, Cavaco I, Hofmann Y, Pedersen RS, Landman E, Mkrtchian 
S, Ingelman-Sundberg M. New insights into the regulation of CYP2C9 gene 
expression: the role of the transcription factor GATA-4. Metab Dispos 2010;38:415-
21. 
37. Nishimura F, Tokuda M, Sasaki D, Mori S, Tsuruda K, Hasegawa H, Yanagihara K, 
Kamihira S.  An instructive case suggesting warfarin resistance which is independent 
on the regulation of the CYP2C9 and VKORC1 genotype. Rinsho Byori 
2011;59:1087-90. 
38. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, 
Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med 
Res 2007;5:8-16. 
39. Ruaño, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, 
Windemuth A, White CM, Duconge J, Holford TR, Wu AHB.  High carrier 
prevalence of combinatorial CYP2C9 i VKORC1 genotypes affecting warfarin dosing. 
Personal Med 2008;5:225-232. 
40. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, 
Newcomb CW, Whitehead AS. Apolipoprotein E genotype and warfarin dosing 
among Caucasians and African Americans. Pharmacogenom J 2008;8:53–60. 
22 
 
41. Božina N, Granić P, Lalić Z, Tramišak I, Lovrić M, Stavljenić-Rukavina A. Genetic 
polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian 
population. Croat Med J 2003;44:425-8. 
42. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, 
Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed 
M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ. 
International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a 
single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 
2010;115:3827-34. 
43. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, 
Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE. Dosing algorithms to 
predict warfarin maintenance dose in Caucasians and African Americans. Clin 
Pharmacol Ther 2008;84:332-9. 
44. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, 
Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB; Clinical 
Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics 
Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and 
warfarin dosing. Clin Pharmacol Ther 2011;90:625-9. 
45. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a 
comprehensive review of the in-vitro and human data. Pharmacogenetics 
2002;12:251-63. 
46. Wysowski DK, Nourjah P, Schwartz L. Bleeding comlications with warfariin use:a 
prevalent adverse effect in regulatory action, Arch Intern Med 2007;167:1414-19. 
47. Hirschl MM, Wollmann C. A 2-year survey of treatment of acute atrial fibrillation in 
an ED. Am J Emerg Med 2011;29:534-40. 
23 
 
48. Gurwitz D, Lunshof JE. Ancestry in translational genomic medicine: handle with care. 
Genome Med 2009;1:24. 
49. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of 
anticoagulant treatment. Chest 2001;119:108-121. 
50. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 
and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for 
thrombotic events to avoid serious bleeding. Genet Med 2008;10:89-98. 
51.  Heeringa J, Van der Kuip D.AM, Hofman A. Prevalence, incidence and lifetime risk 
of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53. 
52. Ioannidis JPA.  Personalized Genetic Prediction: Too Limited, Too Expensive, or Too 
Soon? Ann Intern Med 2009;150:139-141. 
53. Parka SM, Leeb JK, Chunc SI, Leeb HI, Kwona SU, Kanga DW, Kim JS. VKORC1 
and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke 
Patients. J Stroke 2013;15:115-121. 
54. Croatian National Institute of Public Health. Croatian health-statistic for the 2008th 
year. Zagreb, 2008 
55. Leyden JM, Kleinig TJ, Newbury J, et al: Adelaide stroke incidence study: declining 
stroke rates but many preventable cardioembolic strokes. Stroke 2013;44:1226-31. 
 
 
  
24 
 
Tables 
 
Table 1. Inclusion and exclusion criteria for the patients with ischemic stroke that required           
anticoagulant therapy 
Inclusion criteria Exclusion criteria 
1. Previously taking warfarin due to:                         
• atrial fibrillation, mechanical 
heart valves, deep vein 
thrombosis or pulmonary 
embolism 
2. Newly detected atrial fibrillation 
confirmed by HOLTER ECG 
3. Acute dissection of extracranial or 
intracranial arteries 
4. Foramen ovale apertum (FOA) 
with septal aneurysm 
5. Cerebral venous sinus thrombosis 
1. Bleeding detected by brain CT 
scan except in patients with cerebral 
venous sinus thrombosis 
2. Malignancy 
3. Pregnancy 
4. Hepatic and renal insufficiency 
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Table 2. Demographic data, average doses of warfarin (estimated, introduction and 
maintenance doses), anticoagulant effect of warfarin (expressed by the time to reach target 
INR values, time and proportion of time spent within the therapeutic/supratherapeutic INR 
range) and time to achieve a stable daily maintenance dose. 
 
Patients N -/+ 95% CI Median 
Age  106 65.1-70.3 72.0 
Weight  106 73.1-77.2 75.0 
De  106 3.6-4.2 3.8 
Di 106 5.8-6.6 6.0 
Dm 106 3.4-4.0 3.5 
T-Dm 106 9.9-10.7 10.0 
Tm 106 15.7-16.8 16.7 
To  106 0.07-0.7 0.0 
T %  106 74.7-79.5 78.5 
T tg 106 4.1-4.6 4.2 
 
N (number of patients); Age (year, median), Weight (Kg, median), 95% CI (+/-95% 
confidence interval);  De (estimated dose, mg); Di (dose of introduction, mg); Dm (stable 
daily maintenance dose, mg); T-Dm (time to achieve a stable daily maintenance dose, day); 
Tm (time spent within the therapeutic INR range, day); T% (proportion of time spent within 
the therapeutic INR range); To (time spent within the supratherapeutic INR>3.1, day); Ttg 
(time to reach target INR values, day) 
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Table 3. Frequencies of the carriers of CYP2C9*2,*3 and VKORC1 1173C>T gene 
polymorphisms in the group of acute stroke patients, time do achieve target INR≥2 and the 
average stable daily maintenance dose depending on the genotype  
 
genotype N (%) T(days) T 95%CI. Dm (mg) Dm 95%CI 
 106(100%) 4.39 4.12-4.66 3.76 3.4-4.08  
1.CC,wt/wt 18(17%) 5.05 4.47-5.63 5.7 5.1-6.2 
2.CC,wt/*2 14(13.2%) 3.88 3.28-4.49 4.1 3.4-4.8 
3.CC,wt/*3 6(5.6%) 4.55 3.59-5.51 3.8 2.5-5.2 
4.CC,*2/*2 9(8.5%) 4.62 3.56-5.68 3.7 2.7-4.7 
5.CC,*2/*3 5(4.7%) 3.58 2.38-4.78 2.4 1.7-3.0 
6.CT,wt/wt 19(17.9%) 4.93 4.13-5.73 4.9 3.6-5.3 
7.CT,wt/*2 8(7.6%) 4.47 3.69-5.25 2.9 2.3-3.7 
8.CT,wt/*3 13(12.3%) 4.47 3.29-5.65 2.7 2.1-3.2 
10.CT,*2/*3 2(1.9%) 2.45 0.91-3.99 1.3 -1.9-4.4 
11.TT,wt/wt 7(6.6%) 3.89 3.53-4.25 2.3 1.5-2.9 
12.TT,wt/*2 1(0.9%) 3.84  2.5  
13.TTwt/*3 1(0.9%) 2.18  2.0  
14.TT,*2/*3 2(1.9%) 3.210 2.83-3.45 1.5 1.5-1.5 
15.TT,*3/*3 1(0.9%) 1.350  1.0  
 
N (number and percentage of the carriers); 95% CI (+/-95% confidence interval) ;                                                                                                   
T - Average time to achieve target INR ≥ 2 depending on the CYP2C9 and VKORC1  
genotype (day); Dm - Average stable daily maintenance dose (mg), according to the CYP2C9 
and VKORC1 genotype  
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Table 4. Frequencies of the patients according to the severity of neurological deficit at the 
discharge  expressed by mRS, depending on warfarin dosage side effects                                  
(χ2 = 17.87, df = 12, p = 0.1198) 
 
mRS  
N(%)Without 
side effect 
N(%)Side 
effect- 1 
N(%)Side 
effect- 2 
Row - Totals 
0 13 1 1 15 
% 14,44% 14,29% 11,11%  
Row % 86,67% 6,67% 6,67%  
1 23 1 1 25 
% 25,56% 14,29% 11,11%  
Row % 92,00% 4,00% 4,00%  
2 17 1 2 20 
% 18,89% 14,29% 22,22%  
Row % 85,00% 5,00% 10,00%  
3 23 1 0 24 
% 25,56% 14,29% 0,00%  
Row % 95,83% 4,17% 0,00%  
4 9 2 2 13 
% 10,00% 28,57% 22,22%  
Row % 69,23% 15,38% 15,38%  
5 3 1 1 5 
% 3,33% 14,29% 11,11%  
Row % 60,00% 20,00% 20,00%  
6 2 0 2 4 
% 2,22% 0,00% 22,22%  
Row % 50,00% 0,00% 50,00%  
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Total N 90 7 9 106 
 
 
N ( number and frequencies of patients); mRS( modified Rankin Scale); Side effect 1 (minor 
bleeding); Side effect 2 (major bleeding) 
 
 
 
 
 
 
 
 
 
  
